News

November 15, 2017November 15, 2017

EMA Urges European Commission to Approve Takeda’s Adcetris as Therapy for CTCL

News

European regulators have endorsed the use of Takeda‘s Adcetris (brentuximab vedotin) to treat a specific type of cutaneous T-cell lymphoma (CTCL). The Brussels-based Committee for Medicinal Products for Human Use ... Read more

November 14, 2017

Potential Treatment for Advanced CTCL, Mogamulizumab, Under Review in Europe

News

The European Medicines Agency (EMA) agreed to review documents supporting the approval of mogamulizumab — an antibody targeting the CCR4 protein — as a treatment for adults with cutaneous T-cell lymphoma (CTCL) who ... Read more

November 13, 2017November 13, 2017

FDA Approves Adcetris for Most Common Subtypes of Cutaneous T-cell Lymphoma

News

The U.S. Food and Drug Administration (FDA) has approved Seattle Genetics’ Adcetris (brentuximab vedotin) for the treatment of adults with the two most common subtypes of cutaneous T-cell lymphoma (CTCL) — ... Read more

November 9, 2017November 9, 2017

Seattle Genetics Asks FDA to Accept Adcetris as Treatment for Hodgkin’s Lymphoma

News

Seattle Genetics has asked the U.S. Food and Drug Administration (FDA) to expand the label for Adcetris (brentuximab vedotin) to be used in combination with chemotherapy as a first-line treatment ... Read more

November 8, 2017

Novartis Files for Approval of Kymriah for Two Blood Cancers in the EU

News

Novartis continues the process of making Kymriah (tisagenlecleucel) commercially available outside the U.S., now by applying with the European Medicines Agency (EMA) to approve the treatment for two types of ... Read more

November 7, 2017November 7, 2017

Study Links Early Progression to Poorer Survival Outcomes in Follicular Lymphoma Patients

News

New data from the GALLIUM Phase 3 trial (NCT01332968) shows that follicular lymphoma patients who progress within two years of immunochemotherapy have a 26-fold increased risk of death, compared to those ... Read more

November 6, 2017

Bayer to Present Long-term Results of Aliqopa in Treating Indolent Lymphomas at ASH 2017

News

Bayer will present long-term safety and efficacy data from the CHRONOS-1 trial of Aliqopa (copanlisib) in patients with indolent lymphomas at the American Society of Hematology (ASH) 2017 Annual Meeting ... Read more

November 3, 2017

MorphoSys’ MOR208 Receives Breakthrough Therapy Status in US for Relapsed or Refractory DLBCL

News

The U.S. Food and Drug Administration has granted breakthrough therapy designation to MorphoSys‘ MOR208 – in combination with Revlimid (lenalidomide) – for the treatment of adult patients with relapsed or refractory diffuse ... Read more

November 2, 2017

Novartis Asks FDA to Approve Kymriah for Difficult-to-treat DLBCL

News

Novartis has asked U.S. regulators to expand their approval of Kymriah (tisagenlecleucel) to include the treatment of adults with relapsed or refractory diffuse large B-cell lymphoma, or DLBCL. The Food ... Read more

November 1, 2017November 1, 2017

FDA Grants Accelerated Approval to Calquence for Mantle Cell Lymphoma

News

The U.S. Food and Drug Administration has approved AstraZeneca‘s Calquence (acalabrutinib) for the treatment of adult patients with mantle cell lymphoma (MCL) who have received at least one prior therapy. The FDA’s accelerated ... Read more